KCT0001345已完成未知
A single ascending dose escalation clinical trial to investigate safety and pharmacokinetics of VVZ-149 injection in healthy older male volunteers
Vivozon0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 50(Year) 至 85(Year)（—）
- 性别
- Male
入选标准
- •1) Subjects who voluntarily agree to participate and sign an IRB-approved informed consent form (ICF) prior to receiving any of the screening procedures
- •2) Healthy male subjects aged between 50-84, inclusive at screening (the subjects aged 65 years or over can participate only in the single dose trial)
- •3) Subjects with body weights between 50-90 kg, inclusive and with body mass index (BMI) between 18.0-29.9 kg/m2, inclusive
- •4) Healthy subjects satisfying eligibility at screening (medical histories, physical examination, vital sign, electrocardiogram (ECG), hematology, clinical chemistry and urinalysis)
- •5) Subjects who willing to use an medicinal allowed method of contraception or sterility during the study period
排除标准
- •1) Subjects who have a presence or history of clinically significant hepatic, renal, neurologic, immunologic, pulmonary, endocrine, hematological, neoplastic, cardiovascular or psychiatric (e.g. mood disorders or obsessive-compulsive disorder) diseases (subjects with currently well-controlled conditions including hypertension, hyperlipidemia, arthritis, prostatic hypertrophy and cataracts may allow to participate at the discretion of the investigator.)
- •2) Subjects with chronic infection or meaningful acute infection
- •3) Subjects who have a history of clinically significant hypersensitivities or hypersensitivities to the ingredient of same family with investigational product (IP) and other drug (e.g. aspirin and antibiotics)
- •4) Subjects who have a family history of chronic pain or with a first-degree relative with chronic pain
- •5) Subjects who have a clinically significant ECG abnormalities or QTc interval >450 ms
- •6) Subjects who meet the following criteria at screening:
- •? Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) level > 3 times the upper limit of the normal range
- •? Calculated estimate glomerular filtration rate (eGFR) by Modification of Diet in Renal Disease (MDRD) equation < 60 ml/min
- •? Platelets = 75,000/mm3, Hemoglobin = 9 g/dL, Neutrophils absolute = 1000/mm3
- •7) Subjects who show the following vital signs at the screening:
- •? Systolic Blood Pressure (SBP): <92 mmHg or >160 mmHg
- •? Diastolic Blood Pressure (DBP): <50 mmHg or >95 mmHg
- •8) Subjects who have a history of drug abuse or a positive urine screening for drug abuse
- •9) Subjects who have taken any prescribed or herbal medicine within one week before the first administration of the investigational product (IP) or any non-prescribed medicine or vitamin supplement within three days before the first administration of the investigational product (IP) (if all other conditions are satisfied, these subjects may be eligible for the trial as judged by the investigator)
- •10) Subjects who have participated in any other clinical trial within two months before the first administration of the investigational product (IP).
- •11) Subjects who have donated a unit of whole blood within two months or blood components within one month before the first administration of the investigational product (IP), or who have received blood transfusion within one month before the first administration of the investigational product (IP).
- •12) Subjects who consume more than 21 units of alcohol per week (1 unit = 10 g of pure alcohol) or who are unable to abstain from drinking throughout the trial
- •13) Smokers who consume more than average of 10 cigarettes per day over the past three months or who are unable to abstain from smoking throughout the trial
- •14) Subjects who consume or are unable to abstain from products containing caffeine (e.g. coffee, green tea, black tea and sodas) within 24 hours before the first administration of the investigational product (IP) and until discharge from the hospital
- •15) Subjects judged ineligible for the study by the investigator for reasons of medical, psychological, social and geographical conditions causing poor study compliance
研究者
相似试验
进行中（未招募）
1 期
An investigation to investigate whether a single dose of XEN-D0501 is tolerable by type 2 diabetic patients prior to multiple dose trials (to investigate if the compound can effectively regulate diabetes)Type 2 diabetesEUCTR2016-003843-12-DKPILA PHARMA26
已完成
1 期
PAT-SM6 in Patients with Recurrent In-Transit Cutaneous MelanomaRecurrent in-transit cutaneous melanomaCancer - Malignant melanomaSkin - Other skin conditionsACTRN12610000733077Patrys Limited9
尚未招募
不适用
Single dose escalation study in a single center, randomized, single blind, placebo controlled, group comparison design to investigate pharmacokinetics, safety and tolerability of BAY 2253651 after intravenous administration in healthy male subjects.NL-OMON45895Bayer AG35
已完成
不适用
Single dose escalation study in a single-center, randomized, single-blind, placebo-controlled, group-comparison design to investigate pharmacokinetics, safety and tolerability of BAY 2586116 after intravenous administration in healthy male participants.NL-OMON49427Bayer AG35
招募中
不适用
A Phase I clinical study to evaluate the safety and efficacy of allogenic adipose-derived stem cells in the patients with Crohn's fiatula.Symptoms, signs and abnormal clinical and laboratory findings, NECKCT0000188Anterogen6